An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Exscientia to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Exscientia (Nasdaq: EXAI) announced that CEO Andrew Hopkins, CFO Ben Taylor, and CTO Garry Pairaudeau will take part in a fireside chat at the Evercore ISI 4th Annual HealthCONx Virtual Conference on December 2, 2021, at 10:30 a.m. ET. The chat can be accessed via a live webcast on the company's website, with a replay available for 30 days thereafter. Exscientia, an AI-driven pharmatech firm, has pioneered precision oncology and is advancing over 25 clinical programs, including the first AI-designed drug candidates progressing to Phase 1 trials.
Positive
None.
Negative
None.
OXFORD, England--(BUSINESS WIRE)--
Exscientia (Nasdaq: EXAI) today announced that Andrew Hopkins, DPhil., Exscientia’s founder and CEO, Ben Taylor, CFO & Chief Strategy Officer, and Garry Pairaudeau, Chief Technology Officer, will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Virtual Conference on Thursday, December 2, 2021 at 10:30 a.m. ET (3:30 p.m. GMT).
A live webcast of the fireside chat will be available on the Company’s website, under the “Investors & Media” section at investors.exscientia.ai. An archived replay of the webcast will be available for approximately 30 days following the presentation.
About Exscientia
Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our pipeline of internal and partnered programmes demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 25 projects advancing, including the first three AI-designed drug candidates to enter Phase 1 clinical trials.
Exscientia has offices in Oxford, Vienna, Dundee, Miami, Boston, and Osaka. For more information visit us on https://www.exscientia.ai or follow us on Twitter @exscientiaAI.
